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Purpose: To quantitatively analyze and compare the fundoscopic features between
fellow eyes of retinal angiomatous proliferation and typical exudative age-related macular
degeneration and to identify possible predictors of neovascularization.
Methods: Retrospective case–control study. Seventy-nine fellow eyes of unilateral ret-
inal angiomatous proliferation (n = 40) and typical exudative age-related macular degener-
ation (n = 39) were included. Fundoscopic features of the fellow eyes were assessed using
digital color fundus photographs taken at the time of diagnosis of neovascularization in the
ﬁrst affected eye. Grading was performed by two independent graders using Retmarker-
AMD, a computer-assisted grading software based on the International Classiﬁcation and
Grading System for age-related macular degeneration.
Results: Baseline total number and area (square micrometers) of drusen in the central
1,000, 3,000, and 6,000 mm were considerably inferior in the fellow eyes of retinal angio-
matous proliferation, with statistically signiﬁcant differences (P , 0.05) observed in virtually
every location (1,000, 3,000, and 6,000 mm). A soft drusen ($125 mm) area .510,196 mm2
in the central 6,000 mmwas associated with an increased risk of neovascularization (hazard
ratio, 4.35; 95% conﬁdence interval [1.56–12.15]; P = 0.005).
Conclusion: Baseline fundoscopic features of the fellow eye differ signiﬁcantly between
retinal angiomatous proliferation and typical exudative age-related macular degeneration. A
large area (.510,196 mm2) of soft drusen in the central 6,000 mm confers a signiﬁcantly
higher risk of neovascularization and should be considered as a phenotypic risk factor.
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Based on the ﬁrst description by Hartnett et al1 in1992, Yannuzzi et al2 introduced the term retinal
angiomatous proliferation (RAP) to describe a distinct
phenotype of exudative age-related macular degeneration
(eAMD), in which the neovascular complex originates
deeply in the retina.3,4 Retinal angiomatous proliferation
has also been labeled Type 3 neovascularization and the
two terms have been used interchangeably.5,6
Although the prevalence of the disease is low in
asians7,8 and blacks,5 RAP is estimated to represent
12% to 20% of the wet age-related macular degener-
ation (AMD) cases in white populations,2,6,9–11 where
it poses a substantial burden.
It is currently well established that RAP and typical
eAMD present distinct clinical and epidemiologic
features (age, sex, among others12,13), most of them
likely due to genetic differences still not completely
understood.14 Retinal angiomatous proliferation has
been coined a bilaterally aggressive disease with predict-
able symmetry.5 Although deﬁnite proof on the form of
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a prospective randomized clinical trial is still lacking,
the vasogenic potential associated with RAP has been
highlighted by several study groups,9,15,16 reporting
annual and cumulative rates of neovascularization in
fellow eyes far exceeding the typical forms of eAMD.
Considering this alleged aggressiveness, the identiﬁca-
tion of pre-exudative changes in the fellow eye, poten-
tially associated with a higher risk of neovascularization,
is of the utmost importance.
Fundoscopic features such as drusen characteristics
or the presence of pigmentary changes are considered
important ocular risk factors for typical eAMD.17–21
Because of its relevance in clinical practice, the AREDS
group22 created a simpliﬁed point scoring system that
provides baseline risk stratiﬁcation, allows tracking of
progression, and deﬁnes surrogate outcomes for pro-
gression by estimating the 5-year risk of developing
advanced AMD. Despite the well-documented presence
of soft drusen and pigmentary changes in eyes with
RAP,2,4,16,23–27 an objective and rigorous analysis of
their characteristics and an assessment of their possible
inﬂuence in the development of neovascularization in
the fellow eye is lacking. The characterization of phe-
notypic risk factors in fellow eyes of RAP could be of
practical clinical value, since it would alert the eye-care
providers for the possibility of a more aggressive sce-
nario. The purpose of this study was to assess and
compare the fundoscopic changes in fellow eyes of
RAP and typical eAMD and to identify possible pre-
dictors of neovascularization.
Methods
Retrospective case–control study. Enrolled patients
were consecutively selected from a database initially
created as part of a prospective observational study
(Characterization of Early Markers of Choroidal
Neovascularization - CNV Markers,28 NCT00801541)
designed to identify morphological and/or functional
predictors of neovascularization in unaffected fellow
eyes of exudative AMD. At enrollment, every included
subject was asked to sign an informed consent form
in accordance with the Declaration of Helsinki, where
they agreed that their clinical data could be included
in scientiﬁc studies. Bilateral color fundus digital
photographs (CFP), spectral domain optical coherence
tomography, ﬂuorescein angiography, and indocyanine
green angiography were performed at baseline in
every patient, along with a complete ophthalmological
examination. During follow-up, all patients had period-
ical visits, where the ophthalmological examination
and optical coherence tomography were always
repeated. If the study eye (fellow eye) developed
neovascularization, its incidence, time of occurrence,
and phenotype were registered. All the diagnoses were
conﬁrmed by two of three senior retina specialists (R.S.,
M.d.L.C., or J.F.), after reviewing the ocular changes
using multimodal retinal imaging (CFP, spectral
domain optical coherence tomography, ﬂuorescein
angiography, and indocyanine green angiography).
The criteria used for RAP diagnosis have already
been described by our group.29,30
For the purposes of this study, we identiﬁed and
selected consecutive patients with unilateral RAP
(Group 1) from the above-mentioned database. The
same database was also used to identify consecutive
patients with unilateral typical eAMD, to create the
control group (Group 2). The following eligibility
criteria were considered for patient selection in both
groups: 1) any race and either sex, 2) age $50 years,
3) diagnosis of unilateral typical eAMD or RAP at
baseline, and 4) fellow eye (study eye) without any
signs of neovascularization at enrollment. Patients
with ophthalmologic comorbidities (other than age-
related maculopathy) likely to jeopardize the grading
of the color fundus pictures were excluded from the
study.
Color Fundus Photograph Grading
The mydriatic CFP of the unaffected fellow eye used
for grading were obtained at the time of diagnosis of
neovascularization in the non–study eye using a Zeiss
FF450 Fundus Camera equipped with a Nikon high-
resolution camera. All the fundus images were centered
at the fovea, with a 30° ﬁeld of view and a 1,594 ·
1,326 pixel resolution (50% of maximum resolution)
was used for grading purposes. Grading took place at
the Coimbra Ophthalmology Reading Center by two
independent graders certiﬁed by this institution and
was performed using RetmarkerAMD (Retmarker SA,
Coimbra, Portugal), a computer-assisted grading soft-
ware developed according to the guidelines of the Inter-
national Classiﬁcation and Grading System for AMD.31
Both free forms and predeﬁned circles (63, 125, 175,
250, and 500 mm) are available for grading and allow
for an accurate quantiﬁcation of fundus features in dig-
ital CFP, including drusen, pigmentary changes, geo-
graphic atrophy (GA), or exudative lesions (Figure 1).
In addition to a categorical depiction of variables, such
as the number (0, 1–9, 0–19, $20) and area occupied
by drusen (,1%, ,10%, ,25%, ,50%, $50%), the
software allows its quantiﬁcation as continuous varia-
bles, thus reﬂecting the real (absolute) number and area
of drusen.21 The grading results are readily accessible
on screen and can be easily exported as a Microsoft
Excel ﬁle for further statistical analysis.
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Statistical Analysis
Distribution of the several parameters was assessed
with Mann–Whitney U tests, and inﬂuence of age as
a covariate was explored with factorial analyses of
variance.
Receiver operating characteristic curves and Cox
proportional hazard models were used for determining
cutoffs and evaluating conversion risks, respectively.
Alpha was deﬁned at 0.05 and all analyses were




Seventy-nine fellow eyes of RAP (Group 1, n = 40)
and unilateral typical eAMD (Group 2, n = 39) were
included. All the included subjects were white. The
demographic data of both groups are expressed in
Table 1. Patients included in Group 1 were signiﬁ-
cantly older than patients included in Group 2 (P ,
0.001). In the RAP group, 40% (n = 16) of the fellow
eyes developed neovascularization during follow-up
(mean ± SD: 33.50 ± 21.10 months). The average time
to conversion of the fellow eye was 20.56 ± 10.84
months. The cumulative incidence of neovasculariza-
tion was 12.5% at 1 year, 29.6% at 2 years, 39.9% at 3
years, and 47.6% at 4 years. In the eAMD group
(Group 2), conversion to neovascularization occurred
in 48.7% (n = 19) of the fellow eyes, during a follow-
up period of 89.54 ± 25.65 months. The average time
to conversion was 53.32 ± 25.65 months. The cumu-
lative incidence of neovascularization was 2.6% at
1 year, 13.1% at 2 years, 21.9% at 3 years, 31.6% at
4 years, 34.9% at 5 years, and 62.4% at 10 years.
Analysis of the Fundoscopic Changes
Considering the purposes of this analysis, we
initially performed a comparison between the baseline
CFP grading results of the 2 groups (Table 2). The
total number and area (square micrometers) of drusen
in the central 1,000, 3,000, and 6,000 mm were con-
siderably inferior in the fellow eyes of RAP, with
statistically signiﬁcant differences observed in virtu-
ally every location (1,000, 3,000, and 6,000 mm). When
considering only the total number and area of soft drusen
($125 mm), there were no statistically signiﬁcant differ-
ences between groups in the central 1,000 mm (P = 0.187
and P = 0.118, respectively) or 3,000 mm (P = 0.124 and
Fig. 1. Real-time grading using
RetmarkerAMD (Critical Health
SA) in one of the included sub-
jects of the RAP group. A. Cali-
bration is achieved after manually
identifying the fovea and estab-
lishing the optic disk diameter
(blue dot and arrow, respectively).
The software then generates a ref-
erence grid (B) according to the
International Classiﬁcation and
Grading System for AMD.31
C. Both free forms and predeﬁned
circles (63, 125, 175, 250, and
500 mm) can be used for quanti-
fying fundus features in digital
color fundus photographs, includ-
ing drusen, pigmentary changes,
GA, or exudative lesions. D. The
grading results are readily avail-
able on screen and can be easily
exported as a Microsoft Excel ﬁle
for further statistical analysis.
Table 1. Demographic Characteristics of the Study Population
Group 1—RAP Group 2—Typical eAMD P
n 40 39
RE/LE (%) 18 (45%)/22 (55%) 17 (43.6%)/22 (56.4%) 0.900
Male/female (%) 15 (37.5%)/25 (62.5%) 15 (38.5%)/24 (61.5%) 0.952
Age (mean ± SD) 77.50 ± 6.88 70.87 ± 5.74 ,0.001*
RAP, retinal angiomatous proliferation; eAMD, exudative age-related macular degeneration; RE, right eye, LE, left eye; SD, Standard
deviation.
*P,0.05.
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P = 0.336, respectively). However, in the central
6,000 mm, the total number of drusen $125 mm was
signiﬁcantly smaller (P = 0.021) in the fellow eyes of
RAP, although their area was not (P = 0.078).
Despite the signiﬁcant age difference between groups,
a factorial analysis of variance demonstrated that the
difference in drusen number was not inﬂuenced by the
older age of the patients with RAP. Afterward, to
identify potential phenotypic risk factors for conversion,
we compared the characteristics of fellow eyes of RAP
that developed neovascularization (n = 16) during
follow-up, with those that did not (n = 24). This analysis
revealed that the ﬁrst presented a borderline signiﬁcant
(P = 0.053) superior total area of drusen$125 mm in the
central 6,000 mm (Figure 2). A receiver operating char-
acteristic curve analysis was used to ﬁnd the cutoff value
that better predicts the advent of neovascularization. A
total area of soft drusen ($125 mm).510.196 mm2 was
shown to signiﬁcantly increase the risk of neovasculari-
zation with 68.75% sensitivity and 70.83% speciﬁcity.
The Cox regression analysis revealed an associated haz-
ard ratio of 4.35 (P = 0.005; 95% conﬁdence interval:
1.56–12.15).
Pigmentary changes (hypopigmentation or hyper-
pigmentation) were found in 13 fellow eyes of the
RAP group (32.5%) and in 8 fellow eyes of Group 2
(20.5%). However, the observed differences did not
reach statistical signiﬁcance, regardless of location
(central 1,000, 3,000, or 6,000 mm).
Discussion
In patients with RAP, the presence of small
hemorrhages, soft drusen, and pigmentary changes is
well documented,2,16,23–27 but an accurate analysis of
the fundoscopic features of the fellow eyes was lack-
ing. Using a precise and easily reproducible method-
ology,21,28 we analyzed and compared fundoscopic
changes between two demographically similar popula-
tions of fellow eyes of RAP and typical eAMD.
Although still not widely spread in clinical and/or
research settings, the use of semiautomated image anal-
ysis systems represents a convenient and versatile way
of grading fundus changes, signiﬁcantly reducing the
time and expense associated with manual grading.32
We found that the total number and area of drusen
were signiﬁcantly lower in fellow eyes of RAP, in almost
every location (central 1,000, 3,000, and 6,000 mm).
When considering only drusen $125 mm, the
difference between groups reached statistical signiﬁ-
cance for the total number of drusen in the central
6,000 mm (P = 0.0021), although not for their area
(P = 0.078). The signiﬁcance of these results was
emphasized after excluding age as a possible con-
founding factor. Fujimura et al8 compared drusen area
and characteristics of fundus autoﬂuorescence (FAF)
between fellow eyes of Japanese patients with polyp-
oid choroidal vasculopathy (PCV) (n = 95), typical
Table 2. Grading Results Concerning the Total Number and Area of Drusen in the Central 1,000, 3,000, and 6,000 mm,
Both for the RAP and Typical eAMD Groups
RAP Typical eAMD
Mean SD Mean SD P
Central 1,000 mm
Total no. drusen 6.40 7.19 12.74 12.23 0.014*
Total area of drusen (mm2) 41.28 73.47 89.62 103.89 0.009*
Central 3,000 mm
Total no. drusen 57.65 41.29 99.87 78.63 0.018*
Total area of drusen (mm2) 477.68 496.38 775.49 685.07 0.052
Central 6,000 mm
Total no. drusen 126.85 95.25 251.59 204.98 0.005*
Total area of drusen (mm2) 977.00 962.10 1,955.18 1,858.00 0.020*
RAP, retinal angiomatous proliferation; eAMD, exudative age-related macular degeneration; no., number; SD, Standard deviation.
*P,0.05.
Fig. 2. Box plot showing the difference in the area of drusen $125 mm
in the central 6,000 mm between fellow eyes of RAP that did and did
not develop neovascularization (P = 0.053). Central bars indicate
median values; boxes indicate interquartile ranges, and whiskers extend
to the highest and lowest values.
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eAMD (n = 64), and RAP (n = 4). Despite having
found statistically signiﬁcant differences between the
PCV group and the typical eAMD group, the authors
reported that it was not possible to adequately charac-
terize the RAP group, due to the small number of
subjects included. Another study in Asians, conducted
by Kim et al24 compared the extent and density of
drusen between eyes with RAP (n = 20) and typical
eAMD (n = 24). The fellow eyes of these patients were
also evaluated whenever bilateral neovascularization
was not present. The authors found that the density
of drusen in the macular area was signiﬁcantly higher
in fellow eyes of RAP (n = 10) than in fellow eyes of
typical eAMD (n = 17).24 These ﬁndings are the exact
opposite of ours. Aside from the ethnical differences
between populations, the study of Kim et al24 has
several important limitations that may have inﬂuenced
the disparity of results. First of all, the authors ana-
lyzed a small number of fellow eyes and presented
nonequivalent groups. Furthermore, the evaluation of
drusen extent lacks accuracy, since patients were
divided in groups: small extent (,1/3 of the fundus
photograph), intermediate extent (1/3–2/3 of the fun-
dus photograph), and large extent (.1/3 of the fundus
photograph). Therefore, only a mere estimation of the
total area occupied by drusen was determined. Finally,
in their study drusen density was evaluated only in the
central 3,000 mm, when the International Guidelines
for classiﬁcation and grading of AMD31 consider the
central 6,000 mm. Our sample size along with the clear
and precise methodology with which we evaluated the
total number and area of drusen adds robustness to our
analysis and reinforce the obtained results.
We believe that one possible explanation for the
differences we found between drusen characteristics in
fellow eyes of RAP and typical eAMD may be the
frequent development of GA in eyes with RAP. It was
previously thought that GA in RAP was secondary to
the treatments used.33,34 However, in a recent study
using FAF, McBain et al35 found high rates of GA in
RAP, independently of treatment modalities (photody-
namic therapy or antiangiogenic agents). This ﬁnding
may constitute a consequence of the reduced choroidal
perfusion and thickness in RAP, which may be asso-
ciated with the high vasogenic potential observed in
these patients.24,35,36 Since baseline evaluation of our
patients did not include FAF, a precise determination
of possible areas of GA in our population of fellow
eyes could not be achieved and this constitutes a lim-
itation of our study.
In our study, we have also looked at possible
phenotypic risk factors associated with a higher rate
of conversion. We found that a total area of soft drusen
($125 mm) .510.2 mm2 in the central 6,000 mm was
associated with a higher risk of neovascularization
(hazard ratio, 4.35; 95% conﬁdence interval [1.56–
12.15]; P = 0.005) in fellow eyes of RAP. Although
this result should be interpreted carefully, it constitutes
a clinically relevant ﬁnding since it might allow iden-
tiﬁcation of patients with a high probability of conver-
sion at the time of neovascularization of the ﬁrst
affected eye, in a fast and easy way. Sawa et al16
evaluated the correlation between several determinants
(age, sex, follow-up time, presence of soft drusen, and
presence of reticular pseudodrusen [RPD]) and the
development of RAP in fellow eyes. The authors con-
cluded that a long follow-up and the presence of RPD
were associated with conversion.16 In their analysis,
they included soft drusen as a categorical variable
(present/not present) and did not calculate its area
and number. As previously reported, soft drusen are
a common ﬁnding in RAP23,27 so it is totally justiﬁable
that there was no correlation with conversion when the
variable is assessed categorically. Several authors have
postulated an association between RPD and advanced
forms of AMD.37–40 Both Zweifel et al40 and Hogg
et al37 demonstrated that CFP and red-free are poor
means for the detection of RPD, and diagnosis is best
achieved using infrared or FAF. Since baseline evalu-
ation of our patients did not include either of these
retinal imaging modalities, a quantitative evaluation
of RPD could not be attained, thus representing a lim-
itation of our study.
The presence of pigmentary changes has been
identiﬁed as a risk factor for the development of
CNV in patients with typical eAMD.20,22,41 Campa
et al15 identiﬁed foci of hyperpigmentation in 29
(78.4%) of the 37 fellow eyes of RAP in their study
and suggested that these could constitute an important
risk factor for the development of RAP since it was
present in 90% of those who developed neovasculari-
zation. Although we found foci of hyperpigmentation
in 1/3 of patients in the RAP group and in 20% of
patients in the eAMD group, the difference between
groups was not statistically signiﬁcant, and we found
no correlation with the development of neovasculari-
zation for any of the groups.
Aside from its retrospective nature, the main
limitations of our study are related to multimodal
retinal imaging. Baseline FAF and infrared images
were not available, and although grading of CFP can
reliably evaluate drusen characteristics and pigmentary
changes, this method lacks sensitivity in the determi-
nation of GA and RPD. We do believe, however, that
these limitations have a minor impact in our results.
In conclusion, by using an innovative, meticulous,
and easily reproducible grading methodology, we
found that the total number and area of drusen are
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signiﬁcantly smaller in fellow eyes of RAP and that
a total area of soft drusen ($125 mm) .510,196 mm2
in the central 6,000 mm is strongly associated with the
development of neovascularization.
Key words: age-related macular degeneration, cho-
roidal neovascularization, neovascular phenotypes,
retina, retinal neovascularization, retinal angiomatous
proliferation, type 3 neovascularization.
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